We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+15.43%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
–
Cap. Flow
+$1.36B
Cap. Flow %
97.66%
Top 10 Hldgs %
84.97%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$259M
2
GILD icon
Gilead Sciences
GILD
+$193M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$165M
4
INCY icon
Incyte
INCY
+$117M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$103M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 88.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$252M 18.12%
+4,300,372
New +$259M
IONS icon
2
Ionis Pharmaceuticals
IONS
$9.4B
$209M 15.04%
+7,769,172
New +$165M
GILD icon
3
Gilead Sciences
GILD
$165B
$190M 13.67%
+3,700,000
New +$193M
INCY icon
4
Incyte
INCY
$24.4B
$118M 8.49%
+5,357,149
New +$117M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$126B
$112M 8.1%
+1,404,445
New +$103M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$71.8M 5.17%
+778,126
New +$75M
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$71.3M 5.14%
+2,899,412
New +$73M
ARIA
8
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$54.5M 3.93%
+3,115,371
New +$55.2M
IMGN
9
DELISTED
Immunogen Inc
IMGN
$54.1M 3.9%
+3,262,094
New +$52.9M
ONXX
10
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$47.4M 3.42%
+546,500
New +$50.3M
HALO icon
11
Halozyme
HALO
$12.2B
$44.9M 3.23%
+5,646,519
New +$36M
INVA icon
12
Innoviva
INVA
$1.48B
$34.2M 2.47%
+1,102,311
New +$29.6M
ECYT
13
DELISTED
Endocyte, Inc. Common Stock
ECYT
$30.7M 2.21%
+2,339,345
New +$31.5M
OPTR
14
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
$20.9M 1.51%
+1,446,700
New +$21.1M
INFI
15
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$17.6M 1.27%
+1,089,828
New +$33.7M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.3B
$14.1M 1.02%
+454,800
New +$12.1M
ACHN
17
DELISTED
Achillion Pharmaceuticals
ACHN
$13.7M 0.99%
+1,679,340
New +$12.8M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$12.4B
$9.92M 0.71%
+178,028
New +$11.1M
MDCO
19
DELISTED
Medicines Co
MDCO
$9.32M 0.67%
+302,993
New +$10.1M
IDIX
20
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$4.51M 0.33%
+1,250,000
New +$5.11M
DNDN
21
DELISTED
DENDREON CORPORATION
DNDN
$4.18M 0.3%
+1,014,800
New +$4.32M
TSRX
22
DELISTED
TRIUS THERAPEUTICS INC COM STK (DE)
TSRX
$2.27M 0.16%
+280,000
New +$2.07M
GEVA
23
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$2.25M 0.16%
+53,549
New +$2.44M

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for BB Biotech, which disclosed 23 positions worth $1.39B. Its ten largest holdings account for 85% of the portfolio.

Its largest position is Celgene Corp: 4,300,372 shares worth $252M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets.

  • BB Biotech's largest Q2 2013 buy was Celgene Corp: 4,300,372 shares worth $252M.
  • BB Biotech's ten largest holdings make up 85% of its $1.39B portfolio in Q2 2013.
  • BB Biotech disclosed 23 positions in Q2 2013, its first 13F filing on record.

Based on BB Biotech's 13F filing for Q2 2013, filed 14 Aug 2013.